Crohn’s disease (Q99929804)

8

object named as

Laurent Peyrin-Biroulet

0 references

Silvio Danese

9

object named as

Silvio Danese

0 references

author name string

Giulia Roda

1

0 references

Siew Chien Ng

2

0 references

Paulo Gustavo Kotze

3

0 references

Marjorie Argollo

4

0 references

Antonino Spinelli

6

0 references

Arthur Kaser

Nature Reviews Disease Primers

7

0 references

publication date

2 April 2020

0 references

published in

0 references

volume

6

0 references

issue

1

0 references

cites work

Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

https://api.crossref.org/works/10.1038/S41572-020-0156-2

1 reference

7 January 2021

Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Preventing Collateral Damage in Crohn's Disease: The Lémann Index

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: a prospective population-based study

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Incidence and natural course of inflammatory bowel disease in Korea, 2006-2012: a nationwide population-based study

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

A 30-year Trend Analysis in the Epidemiology of Inflammatory Bowel Disease in the Songpa-Kangdong District of Seoul, Korea in 1986-2015

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Environmental triggers in IBD: a review of progress and evidence.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Increased Burden of Psychiatric Disorders in Inflammatory Bowel Disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Globalisation of inflammatory bowel disease: perspectives from the evolution of inflammatory bowel disease in the UK and China

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Geographical variability and environmental risk factors in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide populationbased study

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Epidemiology of Inflammatory Bowel Disease from 1981 to 2014: Results from a Territory-Wide Population-Based Registry in Hong Kong.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Environmental Risk Factors for Inflammatory Bowel Diseases: an Umbrella Review of Meta-analyses

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Is current smoking still an important environmental factor in inflammatory bowel diseases? Results from a population-based incident cohort

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

The association between environmental factors and the development of Crohn's disease with focusing on passive smoking: A multicenter case-control study in Japan

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Evolving role of diet in the pathogenesis and treatment of inflammatory bowel diseases

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Adherence to a Mediterranean diet is associated with a lower risk of later-onset Crohn's disease: results from two large prospective cohort studies

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Exposure to oral contraceptives increases the risk for development of inflammatory bowel disease: a meta-analysis of case-controlled and cohort studies

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Aspirin, Nonsteroidal Anti-inflammatory Drug Use, and Risk for Crohn Disease and Ulcerative Colitis

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Systematic review with meta-analysis: association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of Crohn's disease and ulcerative colitis exacerbation

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Statins Associated With Decreased Risk of New Onset Inflammatory Bowel Disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

A Review of Dietary Therapy for IBD and a Vision for the Future.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Fine-mapping inflammatory bowel disease loci to single-variant resolution

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Expression of NOD2 in Paneth cells: a possible link to Crohn's ileitis

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Nod2: A Critical Regulator of Ileal Microbiota and Crohn's Disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Immunochip meta-analysis of inflammatory bowel disease identifies three novel loci and four novel associations in previously reported loci.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

IL-10 and IL-10 Receptor Mutations in Very Early Onset Inflammatory Bowel Disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

The genetic background of inflammatory bowel disease: from correlation to causality.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Intestinal epithelial cells: regulators of barrier function and immune homeostasis

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

The intestinal epithelial barrier: a therapeutic target?

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Abnormal activation of autophagy-induced crinophagy in Paneth cells from patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Commensal bacteria direct selective cargo sorting to promote symbiosis.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Paneth cells as a site of origin for intestinal inflammation.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Defective ATG16L1-mediated removal of IRE1α drives Crohn's disease-like ileitis.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Deletion of intestinal epithelial cell STAT3 promotes T-lymphocyte STAT3 activation and chronic colitis following acute dextran sodium sulfate injury in mice

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

IKKα controls ATG16L1 degradation to prevent ER stress during inflammation

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

CD4CD8αα IELs: They Have Something to Say

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Functional intraepithelial lymphocyte changes in inflammatory bowel disease and spondyloarthritis have disease specific correlations with intestinal microbiota

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Gammadelta T Cells in Crohn's Disease: A New Player in the Disease Pathogenesis?

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Intestinal epithelial cell endoplasmic reticulum stress promotes MULT1 up-regulation and NKG2D-mediated inflammation.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Anti-NKG2D monoclonal antibody (NNC0142-0002) in active Crohn's disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Paneth cells and innate mucosal immunity

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Immunopathogenesis of IBD: current state of the art.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Translating Immunology into Therapeutic Concepts for Inflammatory Bowel Disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Early-onset inflammatory bowel disease as a model disease to identify key regulators of immune homeostasis mechanisms

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

The role of neutrophils in the pathogenesis of Crohn's disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Innate Lymphoid Cells in Intestinal Inflammation

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Interleukin-12 and -23 Control Plasticity of CD127( ) Group 1 and Group 3 Innate Lymphoid Cells in the Intestinal Lamina Propria

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

When Insult Is Added to Injury: Cross Talk between ILCs and Intestinal Epithelium in IBD

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4 and CD8 human T-cell functional responses

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

A genome-wide association study identifies IL23R as an inflammatory bowel disease gene

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Fecal and Mucosal Microbiota Profiling in Irritable Bowel Syndrome and Inflammatory Bowel Disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

A microbial signature for Crohn's disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Adherent-invasive in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Adherent-invasive Escherichia coli and Crohnʼs disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Adherent and invasive Escherichia coli is associated with granulomatous colitis in boxer dogs

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Microbial network disturbances in relapsing refractory Crohn's disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Quantitative microbiome profiling disentangles inflammation- and bile duct obstruction-associated microbiota alterations across PSC/IBD diagnoses

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Disease-specific alterations in the enteric virome in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Study of the viral and microbial communities associated with Crohn's disease: a metagenomic approach.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Characterization of fungal dysbiosis in Japanese patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Crohn Disease: Epidemiology, Diagnosis, and Management

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Specific gastroduodenoscopic findings in Crohn's disease: Comparison with findings in patients with ulcerative colitis and gastroesophageal reflux disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Presenting features of inflammatory bowel disease in Great Britain and Ireland

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

The natural history of adult Crohn's disease in population-based cohorts

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Efficacy of early intervention on the bowel damage and intestinal surgery of Crohn's disease, based on the Lémann index

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Perianal Crohn's disease findings other than fistulas in a population-based cohort

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Extraintestinal manifestations and complications in IBD.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Update on the Natural Course of Fistulizing Perianal Crohn's Disease in a Population-Based Cohort

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Natural history and long-term clinical course of Crohn's disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

The difference in extraintestinal manifestations of inflammatory bowel disease for children and adults

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Small-bowel capsule endoscopy: a ten-point contemporary review

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Capsule endoscopy has a significantly higher diagnostic yield in patients with suspected and established small-bowel Crohn's disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

European consensus on the histopathology of inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

European evidence based consensus for endoscopy in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Advanced endoscopic imaging techniques in Crohn's disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Cross-sectional imaging modalities in Crohn's disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Meta‐analysis: diagnostic medical radiation exposure in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: meta-analysis of prospective studies

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Which method is best for imaging of perianal fistula?

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Comparative Accuracy of Bowel Ultrasound Versus Magnetic Resonance Enterography in Combination With Colonoscopy in Assessing Crohn’s Disease and Guiding Clinical Decision-making

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Predicting the Crohn's disease activity index from the Harvey-Bradshaw Index

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Antibody markers in the diagnosis of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Serologic, Genetic, and Clinical Associations with Increased Healthcare Resource Utilization in Inflammatory Bowel Disease.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Combined serological, genetic, and inflammatory markers differentiate non-IBD, Crohn's disease, and ulcerative colitis patients.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

C-reactive protein as a marker for inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Laboratory markers in IBD: useful, magic, or unnecessary toys?

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestiv

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohnʼs disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Disease Phenotype, Activity and Clinical Course Prediction Based on C-Reactive Protein Levels at Diagnosis in Patients with Crohn's Disease: Results from the CONNECT Study.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Diagnostic work-up of inflammatory bowel disease in children: the role of calprotectin assay

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Endoscopic Factors Influencing Fecal Calprotectin Value in Crohn's Disease.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

A Simple Fecal Bacterial Marker Panel for the Diagnosis of Crohn's Disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Emerging concepts in non-invasive monitoring of Crohn's disease.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Blood-Derived DNA Methylation Signatures of Crohn's Disease and Severity of Intestinal Inflammation

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Full-Spectrum Endoscopy Improves Surveillance for Dysplasia in Patients With Inflammatory Bowel Diseases

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Colorectal Cancer in Inflammatory Bowel Disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Development and Validation of a Novel Diagnostic Nomogram to Differentiate Between Intestinal Tuberculosis and Crohn's Disease: A 6-year Prospective Multicenter Study.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Development and Validation of a Novel Prediction Model for Differential Diagnosis Between Crohn's Disease and Intestinal Tuberculosis

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Differential diagnosis of intestinal Behçet's disease and Crohn's disease by colonoscopic findings.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Intestinal Behçet and Crohn's disease: two sides of the same coin

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Differentiating Crohn's disease from intestinal tuberculosis

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Diagnosis and management of inflammatory bowel disease in children.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Value redefined for inflammatory bowel disease patients: a choice-based conjoint analysis of patients' preferences

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Detection and management of early stage inflammatory bowel disease: an update for clinicians

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Inflammatory Bowel Disease Patients' Willingness to Accept Medication Risk to Avoid Future Disease Relapse

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Predictors of Crohn's disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Predictors of severe Crohn's disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Clinical, serological and genetic predictors of inflammatory bowel disease course

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta-analysis of prospective studies

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

High Vitamin D-Binding Protein Concentration, Low Albumin, and Mode of Remission Predict Relapse in Crohn's Disease.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Diagnostic delay in a French cohort of Crohn's disease patients

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

The impact of symptoms, irritable bowel syndrome pattern and diagnostic investigations on the diagnostic delay of Crohn's disease: A prospective study

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Diagnostic delay in Crohn's disease is associated with a complicated disease course and increased operation rate

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Catching the therapeutic window of opportunity in early Crohn's disease.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ('Exit Strategies') in Inflammatory Bowel Disease.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Frequency of glucocorticoid resistance and dependency in Crohn's disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

The role of thiopurines in reducing the need for surgical resection in Crohn's disease: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Infliximab, azathioprine, or combination therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Predicting Pre-emptive Discussions of Biologic Treatment: Results from an Openness and Preference Survey of Inflammatory Bowel Disease Patients and Their Prescribers

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Key insights from therapeutic drug monitoring in Crohn's disease patients

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel Disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Modulation of sphingosine-1-phosphate in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Inflammatory bowel disease in Asia: A systematic review

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Comparison of clinical characteristics and management of inflammatory bowel disease in Hong Kong versus Melbourne.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Role of Th17 Cells in the Pathogenesis of Human IBD.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Modulation of cytokine patterns and microbiome during pregnancy in IBD

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Modulatory Effects of Pregnancy on Inflammatory Bowel Disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Effect of intervention in inflammatory bowel disease on health-related quality of life

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Inflammatory bowel disease-specific health-related quality of life instruments: a systematic review of measurement properties

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

The global burden of IBD: from 2015 to 2025.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

The quality of life in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Relationship between socio-demographic and clinical variables, and health-related quality of life in patients with inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Impact of surgery for Crohn's disease on health-related quality of life

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Fatigue and health-related quality of life in inflammatory bowel disease: results from a population-based study in the Netherlands: the IBD-South Limburg cohort

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Impact of pain on health-related quality of life in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Mechanisms of Quality of Life and Social Support in Inflammatory Bowel Disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Endoscopic Mucosal Healing Predicts Favorable Clinical Outcomes in Inflammatory Bowel Disease: A Meta-analysis

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Development of the Crohn's disease digestive damage score, the Lémann score

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Development of an index to define overall disease severity in IBD.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Intestinal fibrosis in inflammatory bowel disease — Current knowledge and future perspectives

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Fibrogenesis in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

Preventing disability in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021

A validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables

1 reference

https://api.crossref.org/works/10.1038/S41572-020-0156-2

7 January 2021